DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0064805 A1 Obae Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0064805 A1 Obae Et Al US 2011 OO64805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0064805 A1 Obae et al. (43) Pub. Date: Mar. 17, 2011 (54) POROUS CELLULOSE AGGREGATE AND Publication Classification MOLDING COMPOSITION THEREOF (51) Int. Cl. (75) Inventors: Kazuhiro Obae, Tokyo (JP); A69/20 (2006.01) HidekiO O Amakawa, Tokyo (JP); A6IR 9/16 (2006.01) Ichirochiro Ibuki,Ibuki.T Tokyo (JP)JP A6II 3/663/167 (2006.01) (73) Assignee: ASAHIKASE CHEMICALS A63L/92A6II 3/34 308:2006.O1 CORPORATION, Tokyo (JP) CI3K L/02 (2006.01) 21) Appl. No.: 12A926,318 (52) U.S. Cl. ......... 424/464; 424/499; 514/630; 514/622: (21) Appl. No 9 514/474; 514/570; 127/34; 127/37 (22) Filed: Nov. 9, 2010 (57) ABSTRACT Related U.S. Application Data A porous cellulose aggregate characterized by having a sec - - - ondary aggregate structure resulting from aggregation of pri (62) Division of application No. 11/918,979, filed on Oct. mary cellulose particles, having a pore Volume within a par 22, 2007, filed as application No. PCT/JP2006/308414 ticle of 0.265 to 2.625 cm/g, containing I-type crystals and on Apr. 21, 2006. having an average particle size of over 30 to 250 Lim, a specific surface area of 0.1 to less than 20 m/g, a repose angle of 25° (30) Foreign Application Priority Data to less than 44° and a swelling degree of 5% or more, and characterized by having the property of disintegrating in Apr. 22, 2005 (JP) ................................. 2005-124477 Water. Patent Application Publication Mar. 17, 2011 Sheet 1 of 4 US 2011/00648.05 A1 FIG.1 O 9.00 0.01 0.1 10 OO PORE DIAMETER (lum) FIG.2 O 0.001 0.01 0.1 0 OO PORE DIAMETER (lum) Patent Application Publication Mar. 17, 2011 Sheet 2 of 4 US 2011/0064805 A1 Patent Application Publication Mar. 17, 2011 Sheet 3 of 4 US 2011/0064805 A1 Patent Application Publication Mar. 17, 2011 Sheet 4 of 4 US 2011/0064805 A1 US 2011/00648.05 A1 Mar. 17, 2011 POROUS CELLULOSEAGGREGATE AND erty have a high disintegration property, and we realized that MOLDING COMPOSITION THEREOF for conventional cellulose powder, if the swelling property is high, the compactability is not sufficient, and conversely if the TECHNICAL FIELD compactability is high, the Swelling property is low. That is, 0001. The present invention relates to a porous cellulose no cellulose powder having both a high compactability and aggregate that is useful mainly as an excipient in the field of high swelling property has been known. We searched for a chemical engineering, in particular, of pharmaceuticals and method to make the particles porous while keeping the pore of foods, and a compacting (molding) composition thereof. diameter of porous cellulose particles as large as possible and have managed to solve the aforementioned problem. That is, we found that excess aggregation can be controlled, and the BACKGROUND ART inside of the particles can be made porous while keeping the 0002. In the fields of pharmaceuticals, foods and other pore diameter large by using primary cellulose particles hav chemical engineering and the like, it has been a general prac ing a specified range of average width and average thickness tice conventionally to prepare a molded body containing an and giving self-aggregation ability thereto. For the porous active ingredient using cellulose particles such as crystalline cellulose aggregates of Patent Document 1, it is described that cellulose, cellulose powder and the like as an excipient, and when two or more groups of cellulose particles having differ for these cellulose particles, good compactability, fluidity and ent particle size are mixed, and the cellulose dispersion is disintegration property are required. dried, the dispersed cellulose particles having a small average 0003 Patent Document 1 describes a porous cellulose particles size enter between the dispersed cellulose particle aggregate (corresponding to Comparative Example 15-17) components having a large average particle size, and for this having a secondary aggregate structure formed by aggrega reason an excess aggregation of the dispersed cellulose par tion of primary cellulose particles, the aggregate having a ticles having the larger average particle size is inhibited, and pore volume within a particle of 0.265 cm/g to 2.625 cm/g, a large pore Volume is created in the secondary aggregate containing type I crystals, and having an average particle size structure. However, since tight aggregation is formed among of more than 30 um and 250 Lim or less, a specific Surface area two or more groups of cellulose having different average of 1.3-20m/g, a repose angle of 25° or more andless than 44° particle size, the pore diameter of the porous cellulose aggre and properties to disintegrate in water, and a method for gates obtained by the method particularly disclosed in the producing the aforementioned porous cellulose aggregate Example was measured to be small, about 1.5um. Since the comprising a step of drying a dispersion containing two or porous cellulose aggregate of the present invention uses the more groups of primary cellulose particles having a different single primary cellulose particles, they are not aggregated as average particle size and a liquid medium wherein the cellu tightly as the porous cellulose aggregate of the Patent Docu lose dispersion particles have an average particle size of 1 to ment and they are different in having a minimum 3 um pore 110 um. Since the aforementioned porous cellulose aggregate diameter. For the size of pore diameter, the Patent Document of the Patent Document requires two or more groups of pri describes that a clear peak can be recognized in the range of mary cellulose particles having a different average particle 0.1-10 Lum and the median pore diameter, which is a peak top size, different primary cellulose particles prepared by two of the pore distribution and closely related to water perme processes such as grinding dried acid insoluble residue of ability into the particles, is preferably 0.3 um or larger, and commercially available pulp and the like have to be mixed as that although a larger median pore diameter is better, it is at described in Example of the Patent Document. On the other most 5 um considering its distribution. It is described that hand the porous cellulose particles of the present invention with a larger median pore diameter, there is better disintegra can be obtained advantageously with a single process without tion property, but it is speculated that in practice it is difficult going through a process of grinding or the like. The porous to obtain a large median pore diameter of 3 um or larger by the cellulose aggregates of the present invention can be obtained production method according to the Patent Document. The by a single process by making the primary cellulose particles porous cellulose aggregates of the present invention has an to have a specified range of average width and average thick advantage that porous cellulose aggregates having a large ness and by making flexible, thereby promoting entanglement median pore diameter of 3 um or above, which can not be of primary cellulose particles without being limited by the obtained by the production method of the Patent Document, major axis of the primary cellulose particles, in other words can be prepared by a single step without requiring mixing of by giving self aggregation ability thereto, and are clearly the different primary cellulose particles prepared through two different from that described in the Patent Document interms steps. of the production method. In addition, because the pore size 0004 Patent Document 2 describes porous cellulose par of the secondary aggregate structure of the porous cellulose ticles (corresponding to Comparative 6 of the present appli particles according to the Patent Document is Smaller than cation) having a crystal structure type I, having pores of that of the porous cellulose aggregates of the present inven diameter of 0.1 umor above and a porous rate of 20% or above tion, and the Swelling degree is lower in water, the disintegra and containing 90% by weight or above of a fraction with 350 tion property is sometimes not sufficient for making tablets mesh and above, which is obtained by mixing cellulose par for a formulation that severely requires disintegration prop ticles with the third component such as a crystalline com erty in the case of drugs which is insoluble in water, and even pound or the like that is insoluble or hard to be soluble in in the case of soluble drugs, when a water repellent additives water but soluble in an organic solvent, by granulating and Such as magnesium Stearate and the like has to be added to drying the mixture using water or a water Soluble organic avoid problems in tablet pressing Such as sticking and the like. Solvent and then extracting/removing the third component We have investigated in detail the particle structure which with an organic solvent. The porous cellulose particles controls disintegration property, and as a result confirmed described in this document is entirely different from the again that the cellulose particles having a high Swelling prop porous cellulose aggregates of the present invention in the US 2011/00648.05 A1 Mar. 17, 2011 particle structure, because the primary cellulose particles volume of 2.0-2.9 cm/g, the fluidity and disintegration prop form Such a homogeneous continuous film-like tight strong erty were good but the compactability was unsatisfactory, cellulose wall structure that the boundaries of the particles while with larger apparent specific volume of 3.0-3.2 cm/g, become unclear.
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Rhinitis - Allergic (1 of 15)
    Rhinitis - Allergic (1 of 15) 1 Patient presents w/ signs & symptoms of rhinitis 2 • Consider other classifi cations of rhinitis DIAGNOSIS No - Please see Rhinitis Is allergic rhinitis - Nonallergic disease confi rmed? management chart Yes 3 ASSESS DURATION & SEVERITY OF ALLERGIC RHINITIS A Non-pharmacological therapy • Allergen avoidance • Patient education VAS <5 VAS ≥5 B Pharmacological therapy B Pharmacological therapy • Antihistamines (oral/nasal), &/or • Corticosteroids (nasal), w/ or without • Corticosteroids (nasal), or • Antihistamines (nasal), or • Cromone (nasal), or • LTRA • Leukotriene receptor antagonists (LTRA)MIMS TREATMENT © See next page Specifi cally for patients w/ asthma Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B167 © MIMS Pediatrics 2020 Rhinitis - Allergic (2 of 15) Previously treated symptomatic Previously treated symptomatic patient (VAS <5) on antihistamines patient (VAS ≥5) on intensifi ed (oral/nasal) &/or corticosteroids (nasal) therapy w/ corticosteroids (nasal) w/ or without antihistamines (nasal) Intermittent Persistent symptoms, symptoms or without allergen w/ allergen exposure exposure B Pharmacological therapy B Pharmacological therapy • Step down or discontinue therapy • Continue or step up therapy Untreated REASSESS DISEASE SEVERITY VAS symptomatic patient DAILY UP TO DAY 3 (VAS <5 or ≥5) 4 CONTINUE Yes THERAPY & STEP EVALUATION VAS <5 DOWN THERAPY1 Improvement of symptoms? No VAS ≥5 B Pharmacological therapy • Step-up therapy REASSESS DISEASE SEVERITY MIMSVAS DAILY UP TO DAY 7 4 Yes EVALUATION VAS <5 Improvement of symptoms? No TREATMENT © VAS ≥5 See next page Continue therapy if symptomatic; consider step-down or discontinuation of therapy if symptoms subside Not all products are available or approved for above use in all countries.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2017-019186 on 20 March 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 29, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2017-019186 on 20 March 2019. Downloaded from Potentially inappropriate prescriptions and omissions in pediatrics: detection by POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) in the emergency unit and in the ambulatory setting. ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2017-019186 Article Type: Research Date
    [Show full text]
  • Alimemazine Tartrate 30Mg/5Ml Syrup Is a Clear Skin Sensitisation) Colourless to Very Pale Yellow Syrupy Liquid • Skin Rashes with a Smell of Apricots
    • Unusual production of breast milk in men and What Alimemazine syrup looks like and PACKAGE LEAFLET: INFORMATION FOR THE USER women contents of the pack • Breast enlargement in men Alimemazine Tartrate 7.5mg/5ml Syrup is a • Loss of menstrual periods clear bright straw coloured syrupy liquid with Alimemazine Tartrate 7.5mg /5 ml Syrup • Difficulty in getting or maintaining an erection a smell of apricots. It is available in glass bottles or in ejaculating (impotence) of 100ml. Alimemazine Tartrate 30mg /5 ml Syrup • Skin redness, swelling and itching (contact Alimemazine Tartrate 30mg/5ml Syrup is a clear skin sensitisation) colourless to very pale yellow syrupy liquid • Skin rashes with a smell of apricots. It is available in glass Read all of this leaflet carefully before 2. WHAT YOU NEED TO KNOW BEFORE Reporting of side effects bottles of 100ml. you start taking this medicine because it YOU TAKE ALIMEMAZINE If you get any side effects, talk to your doctor Marketing Authorisation Holder and contains important information for you. or pharmacist. This includes any possible side Manufacturer Do not take alimemazine if: • Keep this leaflet. You may need to read it effects not listed in this leaflet. You can also Marketing Authorisation Holder • You are allergic (hypersensitive) to: again report side effects directly via the Yellow Card Zentiva Pharma UK Limited, - alimemazine tartrate or any of the other • If you have any further questions, ask your Scheme at: www.mhra.gov.uk/yellowcard or 12 New Fetter Lane, London, EC4A 1JP, UK. ingredients in this medicine(listed in section doctor or pharmacist search for MHRA Yellow Card in the Google 6 below).
    [Show full text]
  • WO 2U11/154U12 a L
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 15 December 2011 (15.12.2011) WO 2U11/154U12 A l (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/415 (2006.01) A61K 9/20 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/DK201 1/050207 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 June 201 1 (10.06.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2010 00506 10 June 2010 (10.06.2010) DK Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): LIFE- GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, CYCLE PHARMA A S [DK/DK]; Kogle Alle 4, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, DK-2970 H0rsholm (DK).
    [Show full text]
  • Experimental Evaluation of Synergistic Action Between Antibiotics and the Antipsychotic Antimicrobial Tri-Flupromazine
    International Journal of Microbiology Research ISSN: 0975-5276 & E-ISSN: 0975-9174, Volume 5, Issue 4, 2013, pp.-430-434. Available online at http://www.bioinfopublication.org/jouarchive.php?opt=&jouid=BPJ0000234 EXPERIMENTAL EVALUATION OF SYNERGISTIC ACTION BETWEEN ANTIBIOTICS AND THE ANTIPSYCHOTIC ANTIMICROBIAL TRIFLUPROMAZINE DEBNATH S.1, PALCHOUDHURI S. 2, CHATTERJEE N.3, SINHAROY D.2, BHOWMICK S.4, PAL T.K.3, DAS S.5 AND DASTIDAR S.G.2* 1Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata- 700 032, West Bengal, India. 2Department of Microbiology, Herbicure Healthcare Bio-herbal Research Foundation, Kolkata- 700104, West Bengal, India. 3Bio-Equivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata- 700 032, West Bengal, India. 4Consultant Clinical Pharmacologist, Peerless Hospital Hospitex & Research Center, Kolkata- 700 094, West Bengal, India. 5Department of Physics, Jadavpur University, Kolkata-700 032, West Bengal, India. *Corresponding Author: Email- [email protected] Received: April 30, 2013; Accepted: May 23, 2013 Abstract- Significant antimicrobial action of the antipsychotic drug triflupromazine (Tp) against various genera of bacteria has been evaluated extensively in previous studies. This present investigation was designed to study whether this phenothiazine is able to augment action of an antibiotic when tested in combination. A total of twelve different bacterial strains belonging to various genera were used and tested to be sen- sitive against many antibiotics and the non antibiotic Tp. The Minimum inhibitory concentration (MIC) of all the test bacteria with respect to the antibiotics ranged fron 2- 50 µg/ml. In case of Tp, MIC ranged from 25-200 µg/ml. Disc diffusion assays revealed synergism between Tp and penicillin, ampicillin, carbenicillin, streptomycin (Sm), gentamicin and ciprofloxacin.
    [Show full text]
  • Principios Activos Fotosensibles
    PRINCIPIOS ACTIVOS FOTOSENSIBLES PROTEGE A TUS PRODUCTOS DE LA FOTODEGRADACIÓN PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]